Buscar

Estamos realizando la búsqueda. Por favor, espere...

Detalle_Publicacion

Driving role of head and neck cancer cell secretome on the invasion of stromal fibroblasts: mechanistic insights by phosphoproteomics

Abstract: Background Cancer-associated fibroblasts (CAFs) are major players in tumor-stroma communication, and participate in several cancer hallmarks to drive tumor progression and metastatic dissemination. This study investigates the driving effects of tumor-secreted factors on CAF biology, with the ultimate goal of identifying effective therapeutic targets/strategies for head and neck squamous cell carcinomas (HNSCC). Methods Functionally, conditioned media (CM) from different HNSCC-derived cell lines and normal keratinocytes (Kc) were tested on the growth and invasion of populations of primary CAFs and normal fibroblasts (NFs) using 3D invasion assays in collagen matrices. The changes in MMPs expression were evaluated by RT-qPCR and kinase enrichment was analyzed using mass spectrometry phosphoproteomics. Results Our results consistently demonstrate that HNSCC-secreted factors (but not Kc CM) specifically and robustly promoted pro-invasive properties in both CAFs and NFs, thereby reflecting the plasticity of fibroblast subtypes. Concomitantly, HNSCC-secreted factors massively increased metalloproteinases levels in CAFs and NFs. By contrast, HNSCC CM and Kc CM exhibited comparable growth-promoting effects on stromal fibroblasts. Mechanistically, phosphoproteomic analysis predominantly revealed phosphorylation changes in fibroblasts upon treatment with HNSCC CM, and various promising kinases were identified: MKK7, MKK4, ASK1, RAF1, BRAF, ARAF, COT, PDK1, RSK2 and AKT1. Interestingly, pharmacologic inhibition of RAF1/BRAF using sorafenib emerged as the most effective drug to block tumor-promoted fibroblast invasion without affecting fibroblast viability Conclusions Our findings demonstrate that HNSCC-secreted factors specifically fine tune the invasive potential of stromal fibroblasts, thereby generating tumor-driven pro-invasive niches, which in turn to ultimately facilitate cancer cell dissemination. Furthermore, the RAF/BRAF inhibitor sorafenib was identified as a promising candidate to effectively target the onset of pro-invasive clusters of stromal fibroblasts in the HNSCC microenvironment.

 Fuente: Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie, 2023, 158, 114176

Editorial: Editions Scientifiques Elsevier

 Fecha de publicación: 01/01/2023

Nº de páginas: 12

Tipo de publicación: Artículo de Revista

 DOI: 10.1016/j.biopha.2022.114176

ISSN: 0753-3322,1950-6007

 Proyecto español: FPU20/01588

Url de la publicación: https://doi.org/10.1016/j.biopha.2022.114176

Autoría

PRIETO-FERNÁNDEZ, LLARA

VILLARONGA, MARÍA DE LOS ÁNGELES

HERMIDA-PRADO, FRANCISCO

HIJAZI, MARUAN

MONTORO-JIMÉNEZ, IRENE

PEVIDA, MARTA

LLAMES, SARA

RODRIGO, JUAN PABLO

CUTILLAS, PEDRO

GARCÍA-PEDRERO, JUANA MARÍA

ÁLVAREZ-TEIJEIRO, SAÚL